Data driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer

Breast Cancer Research and Treatment

Volumn 120, Issue 3, 2010, Pages 567-579

  Karn, Thomas ^a   Metzler, Dirk ^b   Ruckhäberle, Eugen ^a   Hanker, Lars ^a   Gätje, Regine ^a   Solbach, Christine ^a   Ahr, Andre ^a   Schmidt, Marcus ^c   Holtrich, Uwe ^a   Kaufmann, Manfred ^a   Rody, Achim ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Bimodal markers; Breast cancer; Cutoff; Distribution pooling meta analysis; Microarray

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; ARTICLE; BIOCHEMISTRY; BREAST CANCER; CELL PROLIFERATION; CLINICAL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; STRATEGIC PLANNING;

AREA UNDER CURVE; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENES, ERBB-2; HUMANS; KAPLAN-MEIERS ESTIMATE; KI-67 ANTIGEN; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; NORMAL DISTRIBUTION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 77950910452     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0416-z     Document Type: Article

References (66)

1. Coates A, Goldhirsch A, Gelber R, International Breast Cancer Study Group (2002) Overhauling the breast cancer overview: are subsets subversive? Lancet Oncol 3(9): 525-526. doi: 10.1016/ S1470-2045(02)00842-852
2. Cole BF, Gelber RD, Gelber S, Coates AS, Goldhirsch A (2001) Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet 358(9278):277-286. doi: 10.1016/S0140-6736(01)05483-6 (Pubitemid 32738966)
3. Sylvester R, Collette L, Duchateau L (2000) The role of metaanalyses in assessing cancer treatments. Eur J Cancer 36(11): 1351-1358. doi:10.1016/S0959-8049(00)00125-8 (Pubitemid 30421138)
4. Ein-Dor L, Zuk O, Domany E (2006) Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci USA 103(15):5923-5928. doi: 10. 1073/pnas.0601231103
5. Cheadle C, Vawter MP, Freed WJ, Becker KG (2003) Analysis of microarray data using Z score transformation. J Mol Diagn 5(2): 73-81 (Pubitemid 36553428)
6. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci. USA 95(25): 14863-14868. doi:10.1073/pnas.95. 25.14863
7. Getz G, Levine E, Domany E (2000) Coupled two-way clustering analysis of gene microarray data. Proc Natl Acad Sci USA 97(22): 12079-12084. doi: 10.1073/pnas.210134797
8. Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA, Valero V, Booser D, Pippen JE Jr, Vukelja S, Gomez H, Mejia J, Barajas LJ, Hess KR, Sneige N, Hortobagyi GN, Pusztai L, Symmans WF (2007) Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol 8(3): 203-211, doi:10.1016/S1470-2045(07)70042-6 (Pubitemid 46304454)
9. Ahr A, Karn T, Solbach C, Seiter T, Strebhardt K, Holtrich U, Kaufmann M (2002) Identification of high risk breast-cancer patients by gene expression profiling. Lancet 359(9301): 131-132. doi:10.1016/S0140-6736(02)07337-3 (Pubitemid 34112543)
10. Rody A, Holtrich U, Gaetje R, Gehrmann M, Engels K, von Minckwitz G, Loibl S, Diallo-Danebrock R, Ruckhäberle E, Metzler D, Ahr A, Solbach C, Kam T, Kaufmann M (2007) Poor outcome in estrogen receptor-positive breast cancers predicted by loss of Plexin B1. Clin Cancer Res 13(4): 1115-1122. doi:10.1158/1078-0432.CCR-06-2433 (Pubitemid 46424050)
11. Rody A, Karn T, Ruckhäberle E, Hanker L, Metzler D, Müller V, Solbach C, Ahr A, Gätje R, Holtrich U, Kaufmann M (2009) Loss of Plexin B1 is highly prognostic in low proliferating ER positive breast cancers-results of a large scale microarray analysis. Eur J Cancer 45(3): 405-413
12. Ruckhäberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiffmann S, Grösch S, Geisslinger G, Holtrich U, Karn T, Kaufmann M (2008) Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat 112(1):41-52. doi: 10.1007/s10549-007-9836-9
13. Rody A, Karn T, Solbach C, Gaetje R, Munnes M, Kissler S, Ruckhäberle E, Minckwitz GV, Loibl S, Holtrich U, Kaufmann M (2007) The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial. Breast 16(3): 235-240. doi:10.1016/j.breast.2007.02.006 (Pubitemid 46796861)
14. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365(9460): 671-679 (Pubitemid 40260888)
15. Minn AJ, Gupta GP, Padua D, Bos P, Nguyen DX, Nuyten D, Kreike B, Zhang Y, Wang Y, Ishwaran H, Foekens JA, van de Vijver M, Massagué J (2007) Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci USA 104( 16): 6740-6745. doi : 10.1073/pnas.0701138104 (Pubitemid 47175571)
16. Creighton CJ, Kent Osborne C, van de Vijver MJ, Foekens JA, Klijn JG, Horlings HM, Nuyten D, Wang Y, Zhang Y, Chamness GC, Hilsenbeck SG, Lee AV, Schiff R (2009) Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat 114(2):287-299. doi: 10.1007/s10549-008-0017-2
17. Schmidt M, Böhm D, von Törne C, Steiner E, Puhl A, Pilch H, Lehr HA, Hengstler JG, Kölbl H, Gehrmann M (2008) The humoral immune system has a key prognostic impact in nodenegative breast cancer. Cancer Res 68(13):5405-5413. doi: 10. 1158/0008-5472.CAN-07-5206
18. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, d'Assignies, Bergh J, Lidereau R, Ellis P, Harris AL, Klijn JG, Foekens JA, Cardoso F, Piccart MJ, Buyse M, Sotiriou C (2007) TRANSBIG Consortium. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13(11): 3207-3214
19. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98(4): 262-272 (Pubitemid 43264710)
20. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A, Bergh J, Foekens JA, Klijn JG, Larsimont D, Buyse M, Bontempi G, Delorenzi M, Piccart MJ, Sotiriou C (2007) Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25(10): 1239-1246. doi:10.1200/JCO.2006.07.1522 (Pubitemid 46640570)
21. Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, Gillet C, Ellis P, Ryder K, Reid JF, Daidone MG, Pierotti MA, Berns EM, Jansen MP, Foekens JA, Delorenzi M, Bontempi G, Piccart MJ, Sotiriou C (2008) Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 9: 239. doi: 10.1186/ 1471-2164-9-239 (Pubitemid 351804039)
22. Zhang Y, Sieuwerts AM, McGreevy M, Casey G, Cufer T, Paradiso A, Harbeck N, Span PN, Hicks DG, Crowe J, Tubbs RR, Budd GT, Lyons J, Sweep FC, Schmitt M, Schittulli F, Golouh R, Talantov D, Wang Y, Foekens JA (2009) The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Res Treat. doi: 10.1007/s 10549-008-0183-192
23. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, Liu ET, Miller L, Nordgren H, Ploner A, Sandelin K, Shaw PM, Smeds J, Skoog L, Wedren S, Bergh J (2005) Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7(6): R953-R964. doi:10.1186/bcr1325
24. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA. 102(38):13550-13555. doi:10.1073/ pnas.0506230102 (Pubitemid 41420886)
25. Ivshina AV, George J, Senko O, Mow B, Putti T, Smeds J, Lindahl T, Pawitan Y, Hall P, Nordgren H, Wong John EL, Liu ET, Bergh J, Kuznetsov VA, Miller LD (2006) Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66(21): 10292-10301. doi:10.1158/ 0008-5472.CAN-05-4414 (Pubitemid 44799747)
26. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, Kingsley C, Dairkee S, Meng Z, Chew K, Pinkel D, Jain A, Ljung BM, Esserman L, Albertson DG, Waldman FM, Gray JW (2006) Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10(6): 529-541. doi:10.1016/j.ccr.2006.10. 009 (Pubitemid 44854748)
27. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massagué J (2005) Genes that mediate breast cancer metastasis to lung. Nature 436(7050): 518-524. doi:10.1038/nature03799 (Pubitemid 41112921)
28. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gómez HL, Hortobagyi GN, Pusztai L (2006) Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24(26): 4236-4244. doi: 10.1200/JCO.2006.05.6861 (Pubitemid 46630780)
29. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D, Goldstein D, Duss S, Nicoulaz AL, Brisken C, Fiche M, Delorenzi M, Iggo R (2005) Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24(29): 4660-4671. doi: 10.1038/ sj.onc.1208561. (Pubitemid 41032603)
30. Miller WR, Larionov AA, Renshaw L, Anderson TJ, White S, Murray J, Murray E, Hampton G, Walker JR, Ho S, Krause A, Evans DB, Dixon JM (2007) Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenet Genom 17(10): 813-826. doi: 10.1097/ FPC.0b013e32820b853a (Pubitemid 47462295)
31. The International Genomics Consortium (IGC) The expO project (Expression Project For Oncology) http://www.intgen.org/
32. Yu K, Ganesan K, Tan LK, Laban M, Wu J, Zhao XD, Li H, Leung CH, Zhu Y, Wei CL, Hooi SC, Miller L, Tan P (2008) A precisely regulated gene expression cassette potently modulates metastasis and survival in multiple solid cancers. PLoS Genet 4(7):e1.000129. doi:10.1371/journal.pgen.1000129
33. Januario T, Lackner MR (2009) Gene expression profiling of 30 human breast cancers. Gene Expression Omnibus Series GSE 12763. http://www.ncbi.nlm. nih.gov/geo/query/acc.cgi?acc=GSE12763
34. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, Liao X, Iglehart JD, Livingston DM, Ganesan S (2006) X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9(2):121-132. doi: 10.1016/j.ccr.2006.01.013 (Pubitemid 43202662)
35. Klein A, Wessel R, Graessmann M, Jürgens M, Petersen I, Schmutzler R, Niederacher D, Arnold N, Meindl A, Scherneck S, Seitz S, Graessmann A (2007) Comparison of gene expression data from human and mouse breast cancers: identification of a conserved breast tumor gene set. Int J Cancer 121(3): 683-688. doi : 10.1002/ijc.22630 (Pubitemid 46986504)
36. Marty B, Maire V, Gravier E, Rigaill G, Vincent-Salomon A, Kappler M, Lebigot I, Djelti F, Tourdès A, Gestraud P, Hupé P, Barillot E, Cruzalegui F, Tucker GC, Stern MH, Thiery JP, Hickman JA, Dubois T (2008) Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res 10(6): R101. doi:10.1186/bcr2204
37. Chen DT, Nasir A, Culhane A, Venkataramu C, Fulp W, Rubio R, Wang T, Agrawal D, McCarthy SM, Gruidl M, Bloom G, Anderson T, White J, Quackenbush J, Yeatman T (2009) Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue. Breast Cancer Res Treat, doi: 10.1007/s10549-009-0344-y
38. Affymetrix (2001) Statistical algorithms reference guide, technical report. Affymetrix
39. Gautier L, Cope L, Bolstad BM, Irizarry RA (2004) affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20(3):307-315. doi: 10.1093/bioinformatics/btg405 (Pubitemid 38262761)
40. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5(10):R80. doi: 10.1186/gb-2004-5-10-r80
41. Spyratos F, Ferrero-Poüs M, Trassard M, Hacène K, Phillips E, Tubiana-Hulin M, Le Doussal V (2002) Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer 94(8): 2151-2159. doi: 10.1002/ cncr.10458 (Pubitemid 34411971)
42. de Azambuja E, Cardoso F, de Castro G Jr, Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M (2007) Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12, 155 patients. Br J Cancer 96(10): 1504-1513. doi:10.1038/sj.bjc. 6603756 (Pubitemid 46762956)
43. Venables WN, Ripley BD (2002) Modem Applied Statistics with S, chap 16.3, 4th edn. Springer. ISBN 0-387-95457-0
44. Anderson WF, Chen BE, Jatoi I, Rosenberg PS (2006) Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer. Breast Cancer Res Treat 100(1): 121-126. doi: 10.1007/s 10549-006-9231-y
45. Jatoi I, Chen BE, Anderson WF, Rosenberg PS (2007) Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol 25(13):1683-1690. doi: 10.1200/JCO.2006.09.2106 (Pubitemid 46797948)
46. Polyak K (2007) Breast cancer: origins and evolution. J Clin Invest 117(11):3155-3163. doi: 10.1172/JCI33295
47. Collins LC, Botero ML, Schnitt SJ (2005) Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases. Am J Clin Pathol 123(1): 16-20. doi:10.1309/ HCF035N9WK40ETJ0
48. Nadji M, Gomez-Fernandez C, Ganjei-AzarP, Morales AR (2005) Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5, 993 breast cancers. Am J Clin Pathol 123(1): 21-27. doi:10.1309/4WV79N2GHJ3X1841 (Pubitemid 40066168)
49. Barnes DM, Millis RR, Beex LV, Thorpe SM, Leake RE (1998) Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: the need for quality assurance. Eur J Cancer 34(11): 1677-1682. doi : 10.1016/S0959-8049(98)00149-X
50. Ross JS, Symmans WF, Pusztai L, Hortobagyi GN (2007) Standardizing slide-based assays in breast cancer: hormone receptors, HER2, and sentinel lymph nodes. Clin Cancer Res 13(10):2831-2835. doi:10.1158/1078-0432.CCR-06-2522
51. Badve SS, Baehner FL, Gray RP, Childs BH, Maddala T, Liu ML, Rowley SC, Shak S, Perez EA, Shulman LJ, Martino S, Davidson NE, Sledge GW, Goldstein LJ, Sparano JA (2008) Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 26(15): 2433-2435. doi:10.1200/JCO.2007.13.6424
52. Mann GB, Fahey VD, Feleppa F, Buchanan MR (2005) Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol 23(22): 5148-5154. doi:10.1200/JCO.2005.02.076 (Pubitemid 46224023)
53. Ma XJ, Hilsenbeck SG, Wang W, Ding L, Sgroi DC, Bender RA, Osborne CK, Allred DC, Erlander MG (2006) The HOXB13:IL17BR expression index is a prognostic factor in earlystage breast cancer. J Clin Oncol 24(28): 4611-4619. doi: 10.1200/ JCO.2006.06.6944 (Pubitemid 46630959)
54. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P, Børresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19): 10869-10874. doi: 10.1073/pnas.191367098
55. Gruvberger S, Ringnér M, Chen Y, Panavally S, Saal LH, Borg A, Fernö M, Peterson C, Meltzer PS (2001) Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 61 (16): 5979-5984 (Pubitemid 32762524)
56. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871): 530-536. doi: 10.1038/415530a (Pubitemid 34130608)
57. Lusa L, McShane LM, Reid JF, De Ceceo L, Ambrogi F, Biganzoli E, Gariboldi M, Pierotti MA (2007) Challenges in projecting clustering results across gene expression-profiling datasets. J Natl Cancer Inst 99(22):1715-1723. doi:10.1093/jnci/ djm216 (Pubitemid 351767219)
58. Teschendorff AE, Naderi A, Barbosa-Morais NL, Caldas C (2006) PACK: profile analysis using clustering and kurtosis to find molecular classifiers in cancer. Bioinformatics 22(18): 2269-2275. doi: 10.1093/bioinformatics/btl174 (Pubitemid 44390883)
59. Ertel A, Tozeren A (2008) Switch-like genes populate cell communication pathways and are enriched for extracellular proteins. BMC Genomics 9:3. doi:10.1186/1471-2164-9-3 (Pubitemid 351315034)
60. Gormley M, Tozeren A (2008) Expression profiles of switch-like genes accurately classify tissue and infectious disease phenotypes in model-based classification. BMC Bioinformatics 9: 486. doi: 10.1186/1471-2105-9-486
61. Ertel A, Tozeren A (2008) Human and mouse switch-like genes share common transcriptional regulatory mechanisms for bimodality. BMC Genomics 9(1):628. doi: 10.1186/1471-2164-9-628
62. Sell S, Pierce GB (1994) Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. Lab Invest 70(1):6-22 (Pubitemid 24080100)
63. Pardal R, Clarke MF, Morrison SJ (2003) Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 3(12): 895-902. doi: 10.1038/nrc1232 (Pubitemid 37500174)
64. Sanai N, Alvarez-Buylla A, Berger MS (2005) Neural stem cells and the origin of gliomas. N Engl J Med 353(8): 811-822. doi: 10.1056/NEJMra043666
65. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414(6859):105-111. doi:10.1038/35102167
66. Jordan CT, Guzman ML, Noble M (2006) Cancer stem cells. N Engl J Med 355(12): 1253-1261. doi:10.1056/NEJMra061808